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Abstract
Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor α, is ap-
proved as add-on maintenance treatment for inadequately controlled type 2 severe 
asthma. This systematic review evaluated the efficacy, safety and economic impact 
of dupilumab compared to standard of care for uncontrolled severe asthma. PubMed, 
EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. 
Critical and important asthma-related outcomes were evaluated. The risk of bias and the 
certainty of the evidence were assessed using GRADE. Three RCTs including 2735 sub-
jects >12 years old and 24-52 weeks of follow-up were included. Dupilumab reduced with 
high certainty severe asthma exacerbations (Incidence rate ratio 0.51; 95% CI 0.45-0.59) 
and the percentage use of oral corticosteroid use (mean difference (MD) −28.2 mg/d; 95% 
CI −40.7 to −15.7). Asthma control (ACQ-5), quality of life (AQLQ) and rescue medication 
use [puffs/d] improved, without reaching the minimal important clinical difference: ACQ-5 
MD −0.28 (95% CI −0.39 to −0.17); AQLQ MD +0.28 (95% CI 0.20-0.37); and rescue 
medication MD −0.35 (95% CI −0.73 to +0.02). FEV1 increased (MD +0.15; 95% CI +0.11 
to +0.18) (moderate certainty). There was an increased rate of dupilumab-related adverse 
events (AEs) (moderate certainty) and of drug-related serious AEs (low certainty). The in-
cremental cost-effectiveness ratio of dupilumab versus standard therapy was 464 000$/
QALY (moderate certainty). More data on long-term safety are needed both for children 
and for adults, together with more efficacy data in the paediatric population.
K E Y W O R D S
cost-effectiveness, dupilumab, exacerbations, oral corticosteroids, severe asthma
1  | INTRODUC TION
The main goal in the management of patients with severe asthma is 
achieving disease control and reducing risk of attacks while avoiding 
harm from controller therapies.1,2 Despite extensive efforts, there is 
still a small proportion of patients with severe asthma insufficiently 
controlled with the current medications, with a significant burden 
due to high morbidity and costs.3-8 Current guidelines support the 
targeted approach in uncontrolled severe asthma, and several bio-
logicals are approved for use in these patients.1,2
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IL-4 and IL-13 are key cytokines in driving the initiation and chro-
nicity of type 2 (T2) inflammation, an important inflammatory pathway 
in severe asthma.9-11 Dupilumab is a fully human anti-IL-4 receptor α 
(IL-4Rα) monoclonal antibody that blocks both IL-4- and IL-13-mediated 
signalling pathways. It has been recently approved for adults and ad-
olescents 12 years and older as add-on maintenance treatment for 
severe asthma. According to the European Medicines Agency (EMA), 
dupilumab is recommended for severe asthma with T2 inflammation 
characterized by raised blood eosinophils and/or fractional exhaled ni-
tric oxide (FeNO), inadequately controlled with high-dose inhaled cor-
ticosteroids (ICS) plus another maintenance treatment.12 The US Food 
and Drug Administration (FDA) recommends dupilumab for an eosino-
philic phenotype or for oral corticosteroid (OCS)–dependent asthma.13
The European Academy of Allergy and Clinical Immunology 
(EAACI) is developing clinical practice guidelines for the use of bio-
logicals in patients with severe asthma. To inform key clinical recom-
mendations, a systematic review (SR) evaluated the effectiveness and 
safety of dupilumab for patients with uncontrolled severe asthma.
2  | METHODS
2.1 | Guideline Development Group
The EAACI Asthma Voting Panel and Steering Committee included 
clinicians and researchers with different backgrounds (the complete 
list of experts is available from the EAACI website) who voluntarily 
participate in the EAACI biologics guideline. They are referred to as 
the Guideline Development Group (GDG).
2.2 | Structured question and outcome prioritization
The GDG framed the clinical question as “Is the treatment with 
dupilumab efficacious and safe for patients with severe asthma?” 
The population was defined as subjects with confirmed diagnosis 
of asthma inadequately controlled on ICS and additional controllers. 
The outcomes were prioritized by the GDG using a 1-to-9 scale (7-9: 
critical; 4-6: important; 1-3: of limited importance), as suggested by 
the GRADE approach. The critical outcomes were exacerbations, 
asthma control, quality of life (QoL) and safety (drug-related adverse 
events (AEs) and drug-related serious AE (SAEs)), and the impor-
tant outcomes were lung function (forced expiratory volume in 1 s 
[FEV1]), OCS and ICS use and rescue medication use (Table 1).
The GDG also framed a cost-effectiveness question to assess the 
economic impact of dupilumab versus standard of care. The selected 
outcomes of interest were costs, resource use and the incremen-
tal cost-effectiveness ratios (ICERs) per quality-adjusted life-years 
(QALYs).
2.3 | Search methodology
Electronic algorithms in combination with controlled vocabulary and 
search terms were used to identify relevant randomized controlled 
trials (RCTs) and economic evaluations in (a) MEDLINE (via PubMed, 
January 2019), (b) Cochrane Controlled Trials Register (via The 
Cochrane Library, January 2019) and (c) EMBASE (via Ovid, January 
2019). Search algorithms were adapted to the requirements of each 
database, and validated filters were used to retrieve appropriate de-
signs (Table S1). Additional studies provided by the GDG and previ-
ous SR were also evaluated.
2.4 | Eligibility criteria and selection of studies
The SR included RCTs comparing dupilumab versus placebo added 
to usual care/standard of care in patient with severe asthma, and 
reporting one of the outcomes of interest as formulated by the GDG. 
The SR excluded studies with dose or route not approved by the 
EMA or FDA, papers published as abstract or conference communi-
cations or those not published in English. After initial calibration, two 
TA B L E  1   Structured clinical question
Population Intervention Comparison Outcomes
Adults and 
adolescents 





controlled on ICS 
and additional 
controllers
• An initial dose of 400 mg 
(two 200 mg injections) 
followed by 200 mg 
given every other week, 
or
• An initial dose of 600 mg 
(two 300 mg injections) 
followed by 300 mg 






• Exacerbation rate. Measured by annualized rate of severe exacerbation 
(number of exacerbations per person year), defined as a deterioration 
of asthma requiring: (a) the use of systemic corticosteroids for ≥3 d or 
(b) hospitalization/emergency room visit because of asthma, requiring 
systemic corticosteroids
• Asthma control: assessed by Asthma Control Questionnaire (ACQ-5)
• Quality of life: assessed by asthma quality of life questionnaire (AQLQ)
• Safety (drug-related adverse events; drug-related serious adverse events)
Important
• Reduction in inhaled corticosteroid (ICS) and oral corticosteroid (OCS) 
doses
• Reduction in rescue medication
• Improvement in Prebronchodilator forced expiratory volume in 1 s (FEV1, 
L)
• Reduction in Fraction of exhaled nitric oxide (FeNO)
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reviewers independently screened the search results based on the 
title and abstract, followed by independent assessment of the eligi-
bility based on the full text. In case of disagreement, a third reviewer 
was consulted. References were managed with Endnote version X7 
software (Thomson Reuters).
2.5 | Data extraction and risk of bias assessment
One reviewer independently extracted the main characteristics of 
eligible studies (study design, patient population, mean age of pop-
ulation, follow-up and outcomes of interest), and a second reviewer 
double-checked and confirmed. If needed, authors of included 
studies were contacted to provide additional data. The Cochrane 
Risk of Bias tool for randomized trials was used to assess the risk 
of bias (ROB) of the included studies.14 The ROB was judged as low, 
high or unclear for each domain: random sequence generation, al-
location concealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data and selective 
reporting.
For the health economic analysis, two reviewers extracted 
the main characteristics of included studies (eg type of economic 
evaluation, perspective, time horizon, discounting, sources of in-
formation, model type), relevant outcomes and costs (eg ICERs, 
sensitivity analysis results), sources of funding and conflict of in-
terest. Methodological limitations of the complete economic eval-
uation were evaluated by 2 reviewers using the Consensus on 
Health Economic Criteria (CHEC) checklist.15 Transferability to 
the European context was assessed using the European Network 
of Health Economic Evaluation Databases (EURONHEED) 
checklist.16,17
2.6 | Data synthesis and analysis
The main results of the SR are described narratively and tabulated 
as summary of findings. Data were pooled and meta-analysed using 
Review Manager (Review Manager V.5.3; Cochrane Collaboration) 
using the random-effects model approach. For dichotomous vari-
ables, data were pooled as incidence rate ratios (IRR) or risk ratios 
(RRs). For continuous outcomes, mean differences (MDs) with 95% 
confidence intervals (CI) were used. If mean or standard deviations 
(SD), or changes of mean and SDs from baseline, were not reported, 
standard errors (SE), CI or the correlation coefficient was used. 
Where multiple arms were compared to a common placebo arm, SE 
were adjusted to avoid the unit of analysis error.18
The magnitude of heterogeneity between the included studies was 
calculated using the Higgins I2 statistic interpreted according to the 
Cochrane Handbook guidelines.19 To account for clinical heterogene-
ity, subgroup analysis was predefined if possible by different doses of 
dupilumab (200 mg or 300 mg), baseline eosinophil counts, biomark-
ers (FeNO) and ROB. The median estimate reported in the control 
arms was used as baseline risk to estimate absolute effects. For the 
economic evidence, results are summarized narratively and tabulated, 
including the incremental ratios and the degree of uncertainty.
2.7 | Certainty of the evidence
The certainty (quality) of the evidence of efficacy, safety and 
economic impact was rated for each outcome as high, moderate, 
low or very low, following the GRADE approach and the standard 
GRADE domains (risk of bias, imprecision, inconsistency, indirect-
ness and publication bias).20,21 For the evaluation of imprecision 
for each outcome, the following thresholds for the minimal im-
portant difference (MID) were considered when available: 0.5 for 
ACQ and AQLQ (with disclaimer as calculated pre-/post-treat-
ment), 0.81 puff/d for use of rescue medication and 20% for ex-
haled NO.22-25 For FEV1, the applied MID was 0.2 L, as agreed by 
consensus by the GDG.
3  | RESULTS
3.1 | Studies included and excluded from the 
systematic review
As per the Cochrane Handbook for Systematic Reviews of 
Interventions, the eligibility process of the original studies is sum-
marized using the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) flow chart (Figure 1A,B).
The current search identified in total 3441 citations. After ex-
cluding duplicates and screening the title and abstract, 12 full-text 
papers were evaluated for the efficacy and safety; 9 were excluded 
due to different population of interest, nonrandomized double-blind 
study design or dose not approved by the regulatory authorities, 
and three RCTs were included.26-28For the economic evidence, 35 
full papers were evaluated and only one cost-effectiveness analysis 
was considered suitable for inclusion (Figure 1B).29
3.2 | Characteristic of included studies
The key characteristics of studies included are detailed in Table 2 
and the ones excluded are described in Table S2. The RCTs evalu-
ated included 2735 patients with severe asthma uncontrolled under 
treatment with ICS,26,27 or with OCS,28 plus up to two additional 
controllers. All studies included subjects aged 12 or older, mean age 
(SD) 47.9 years (15.3-51.3). The follow-up under dupilumab treat-
ment ranged from 24 weeks26,28 to 1 year.27
3.3 | Evidence of efficacy and safety
The summary of the results and certainty of evidence per outcome is 
included in Tables 3 and 4.
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F I G U R E  1   Study flow chart. A, Studies 
evaluating the clinical efficacy. B, Studies 




     |  1063AGACHE Et Al.
3.3.1 | Severe asthma exacerbations
Each of the three RCTs reported the annualized severe exacerba-
tion rate assessed at different time points: week 2426,28 and week 
52.27 Overall, dupilumab reduced with high certainty of evidence the 
rate of severe exacerbations compared to placebo (IRR 0.51; 95% CI 
0.45-0.59). There were no differences between the dupilumab dose 
subgroups (200 mg vs. 300 mg) (P = .91). The decrease in asthma 
exacerbations rate was significantly higher in the subgroup of pa-
tients with ≥300 eosinophils/μL at baseline (P = .001): IRR 0.35 (95% 
CI 0.28-0.44) versus 0.63 (95% CI 0.48-0.83) in the subgroup with 
<300 eosinophils/μL. Similarly, patients with high levels of FeNO 
responded better to dupilumab with a significantly higher decrease 
in exacerbations rate (P < .0001): IRR 0.76 (95% CI 0.61-0.95 in the 
low FeNO subgroup (<25 ppb), 0.38 (95% CI 0.28-0.53) in the sub-
group with intermediate increase in FeNO (25 ppb ≤ FeNO <50 ppb) 
and 0.33 (95% CI 0.24-0.46) in the high FeNO subgroup (≥50 ppb) 
(Figure S1).
3.3.2 | Asthma control
All three RCTs measured asthma control using the ACQ-5 scores. 
The pooled results showed that dupilumab improved asthma control 
(MD −0.28; 95% CI −0.39 to −0.17; high certainty of evidence), but 
did not reach the MID threshold of 0.5.22
3.3.3 | Quality of life
Two RCTs reported on the QoL outcome measured by AQLQ.26,27 The 
pooled analysis showed improvement in the QoL (MD +0.28; 95% CI 
TA B L E  2   Characteristics and summary of results of the studies included for the evaluation of dupilumab efficacy, safety and economic 
impact







Mean (SD) Population Intervention Control Follow-up






RCT (N = 1902)
47.9 (15.3) Patients with asthma 
uncontrolled under 
medium- to high-dose ICS 
plus up to two additional 
controllers
Dupilumab 200 mg s.c. every 
2 wk (loading dose, 400 mg).
or
Dupilumab 300 mg s.c. every 









RCT (N = 210)
51.3 (12.6) Patients with severe 
asthma on maintenance 
oral corticosteroids (OCS) 
and high-dose ICS in 
combination with a second 
controller
Dupilumab 300 mg s.c. every 








RCT (N = 776)
48.0 (12.8) Patients with moderate-to-
severe asthma uncontrolled 
on high-dose ICS/long-
acting beta-2 agonist
Dupilumab 200 mg s.c. every 
2 wk (loading dose, 400 mg).
or
Dupilumab 300 mg s.c. every 
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TA B L E  3   Summary of available evidence for the outcomes of interest (listed by outcome)
Dupilumab compared to standard of care for asthma
Population: patients with severe asthma uncontrolled under ICS/OSC and 1-2 additional controllers
Intervention: dupilumab
Comparison: standard of care
Outcomes
No. of participants 
evaluated for a 
particular outcome 
(no. of studies 
pooled for the SR)
Follow-up range







Risk difference with 
dupilumab
Exacerbation Rate Ratio








(0.45-0.59)b  90 per 1000 757 fewer per 1000 
(from 836 fewer to 
655 fewer)
Lung Function






- - MD +0.15 (+0.11 to 
+0.18)b 
Asthma Control
Assessed with Asthma Control 
Questionnaire-5 (ACQ-5)






- - MD -0.28 (-0.39 to 
-0.17)b 
Quality of life
Assessed with Asthma Quality of 
Life Questionnaire (AQLQ)






- - MD +0.28 (+0.2 to 
+0.37)b 
Safety









711 per 1000 85 more per 1000 
(14 fewer to 199 
more)
Safety









56 per 1000 13 more per 1000 
(26 fewer to 98 
more)







- - MD -0.35 (-0.73 to 
+0.02)
Reduction of oral corticosteroid use







- - MD -28.2 (-40.7 to 
-15.7)
Fraction of exhaled nitric oxide 
(FeNO)






- - MD -38.57 (-48.83 
to -28.31)g 
Note: GRADE Working Group grades of evidence.
High certainty: High confidence: the true effect lies close to that of the estimate of the effect.
Moderate certainty: Moderate confidence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different.
Low certainty: Limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the effect.
Very low certainty: Very limited confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
Abbreviations: CI, confidence interval; MD, mean difference; RR, risk ratio.
Explanations
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI). 
aAll three trials in our meta-analysis were industry-funded, all by the same company (Sanofi-Regeneron Pharmaceuticals), and all showed positive 
results. No observational or industry-independent randomized trials were identified to compare with the results derived from the included RCTs. 
bThere was no relevant subgroup effect by dupilumab dose. 
cDowngraded because FEV1 is considered a surrogate outcome of asthma control of symptoms, with a variable correlation with asthma symptoms.35 
(Continues)
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+0.2 to +0.37; high certainty of evidence), but without reaching the 
MID of 0.5.24
3.3.4 | Safety
Dupilumab probably increases (moderate certainty) drug-related AEs 
at 24 weeks: RR 1.12; 95% CI 0.98-1.28; 85 more per 1000 patients; 
from 14 fewer to 199 more. Dupilumab may slightly increase (low cer-
tainty) drug-related SAEs (RR 1.23; 95% CI 0.54-2.77; 13 more AEs 
per 1000 patients from 26 fewer to 98 more) (Figure S2).
3.3.5 | Oral corticosteroids use
Rabe et al28 reported a decrease in OCS use following dupilumab. The 
pooled analysis of the two doses included showed that dupilumab 
reduces with high certainty the percentage use of OCS compared to 
the placebo (MD −28.2 mg/d; 95% CI −40.7 to −15.7).
3.3.6 | Use of rescue medication
Dupilumab reduces the use of rescue medication (MD −0.35 puffs/d; 
95% CI −0.73 to +0.02; high certainty of evidence), without reaching 
the MID of 0.81 puffs/d.22
3.3.7 | Lung function
All three RCTs included reported an increase in FEV1 from base-
line at 12 weeks27 and 24 weeks.26,28 The pooled analysis showed 
that dupilumab increases FEV1 (MD + 0.15 L; 95% CI +0.11 to 
+0.18; moderate certainty), without reaching the MID of 0.2 L. 
There was no difference between dose (200 mg vs. 300 mg) sub-
groups (P = .79). There was better efficacy for patients with ≥300 
eosinophils/µL (P < .0001): 0.23 (95% CI 0.18-0.29) increase in 
FEV1 in the subgroup ≥300 eosinophils/µL at baseline versus 0.08 
(95% CI 0.04-0.13) increase in patients with <300 eosinophils/µL. 
Similarly, FEV1 increased significantly higher (P < .0001) in the sub-
group with high level of FeNO: FEV1 increase 0.07 (95% CI −0.01 to 
0.15) in the FeNO < 25 ppb subgroup, 0.16 (95% CI 0.09-0.22) in the 
25 ppb ≤ FeNO <50 ppb subgroup and 0.34 (95% CI 0.25-0.43) in the 
FeNO ≥ 50 ppb subgroup.
3.4 | FeNO
Two RCTs reported the mean percentage change of FeNO at 24 weeks 
compared to baseline.26,27 The pooled analysis showed that dupilumab 
probably reduces (moderate certainty) FeNO levels (MD −38.57%; 
95% CI −48.83 to −28.31 lower), above the MID of 20% (File S1).25
3.5 | Paediatric subgroup analysis
The data from the paediatric subgroup (12-18 years old) were not 
different from those of the adult group.
3.6 | Evidence of cost-effectiveness
The Markov model assessing dupilumab versus standard therapy was 
tested for the United States.29 The cost of dupilumab 300 mg by sub-
cutaneous injection once every 2 weeks was 2774.65$ (2018 US dol-
lars). The base case analysis reported an ICER of 464 000$/QALY. The 
deterministic sensitivity analysis showed large variations in the ICER 
value from 300 000$ to 1 000 000$ (0.85-0.81 utilities gained). At a 
threshold for willingness to pay of 50 000$, dupilumab is not cost-
effective. The same holds true for the ICER of 269 000$ in the “re-
sponder to treatment” scenario (moderate certainty) (Table 4). The 
moderate certainty derives from limitations in utility estimates for the 
biological and the standard therapy for the nonexacerbation health 
state, in the annual exacerbation rates for standard therapy, and in the 
costs of chronic OCS use. There was also significant indirectness since 
these results may not be applicable outside high-income countries.
4  | DISCUSSION
4.1 | Main findings
The current systematic review shows that dupilumab as an add-on 
treatment for severe asthma uncontrolled under ICS plus a second 
TA B L E  3   (Continued)
dMinimal important difference (MID) of 0.23 L.22 
eThe MID of ACQ-5 is 0.5 points.24 
fThe MID of AQLQ is 0.5 points.24 
gThe MID decrease of the FENO value is defined as a difference larger than 20% for values over 50 ppb or more than 10 ppb for values lower than 
50 ppb from one visit to the next.25 
hDowngraded because FeNO is not consistently considered a good surrogate of inflammation.36,37 
iFor rescue medication use, the MID is a reduction by 0.81 puffs/d.22 
jThe effect may be both harmful and beneficial. 
kFew events were reported in both intervention and control arms, and the effect may be both harmful and beneficial. 
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controller reduces with high certainty the rate of asthma exacerba-
tions and the use of OCS. Although asthma control, quality of life 
and FEV1 are improved and use of rescue medication is reduced, 
dupilumab does not reach above the MID threshold. However, in 
the subgroup with high blood eosinophils and high FeNO the im-
provement in FEV1 is above the MID threshold. Dupilumab probably 
increases short-term drug-related AEs and may increase drug-re-
lated SAEs. With an ICER as add-on therapy of 464 000 (above the 
50 000$ threshold for willingness to pay), it may not be cost-effec-
tive (moderate certainty). However, this threshold has been recently 
contested and the value of individual thresholds was suggested to be 
referred to instead.30,31
Overall, the risk of bias across the included studies was of no 
important concerns for the quality of the evidence. All the studies 
included in the SR were funded by the same company and reported 
positive results raising a concern of publication bias. Moderate cer-
tainty of evidence for the economic impact was available from one 
single study with low risk of bias but with important indirectness 
(single study performed in the United States that may not be appli-
cable to other countries).
4.2 | Results in the context of previous published SR
The current SR shows a similar effect of dupilumab for reduc-
ing asthma exacerbation rate, improving quality of life, asthma 
control and FEV1 as compared to previous SRs.
32,33 These two 
previous SRs showed little to no difference for the AE rate,32,33 
while this systematic review found that dupilumab probably in-
creases the risk of AEs. The difference can be explained by the 
fact that in the current analysis, only drug-related AEs were 
included, excluding AEs related to uncontrolled asthma (ie the 
asthma worsening).
There are some differences between these previous reviews and 
ours. Previous systematic reviews32,33 did not assess the use of rescue 
medication. Only one systematic review examined oral corticosteroid 
use as an outcome.34 This SR reported fewer patient-reported out-
comes33 and included also non–FDA/EMA-approved doses.32,34 The 
current systematic review considered patient-related important out-
comes (ie quality of life) as critical and only included the regulatory ap-
proved doses. Different from the systematic review published by Zayed 
et al, the current SR did not include exclusively studies on patients with 
blood eosinophil counts more than 300/µL. Another systematic review 
published recently only described the results of included trials.34
Another important difference is that previous systematic re-
views only assessed the risk of bias and heterogeneity without 
further interpretation. We assessed the certainty of evidence 
using the GRADE approach, considering the heterogeneity of the 
results, imprecision and indirectness. As examples for surrogate 
outcomes (ie FEV1, FeNO), the evidence was rated down for indi-
rectness and MID was considered when evaluating for imprecision.
4.3 | Limitations and strengths
The current review has several strengths. An exhaustive search from 
three main databases was conducted for both desirable and undesira-
ble effects as well as the cost-effectiveness. Rigorous methods follow-
ing the Cochrane Handbook for Systematic Reviews of Interventions 
were used, including the GRADE approach to rate the certainty of the 
evidence. Only regulatory approved doses were included, together 
with the most updated results available from RCTs. Patient-related 
important outcomes were prioritized. Results are provided in friendly 
tabulated summaries using optimal presentation formats for patients, 
clinicians and policymakers.
There are limitations as well to the current SR. Only studies 
published in English were included. However, we screened studies 
included in previous SR and obtained additional studies through 
the GDG, which made it unlikely that key studies were missed. 
Observational studies that could inform outcomes with low quality 
of evidence (ie serious adverse events) were not included. We did not 
conduct a “the novo” economic analysis for the cost-effectiveness 
TA B L E  4   Summary of available evidence on economic impact. Comparison: Dupilumab in addition to standard therapy vs. standard 
therapy




























Abbreviations: $, US dollar;ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
aIncremental cost and effect due to the addition of dupilumab. 
bMarkov model study with low risk of bias (CHEC score 13 or higher). 
cOne single study performed in the United States. The results may not be applicable to other countries. 
dThe deterministic sensitivity analysis showed large variations in the ICER value from 300 000$ to 1 000 000$ (0.85-0.81 utilities gained, 
respectively). Furthermore, at a threshold of 50 000, the probability for dupilumab to be cost-effective was 0%. 
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outcomes. Instead, a rigorous and explicit critical appraisal of the 
economic evidence was done, which might be useful for the decision 
of using dupilumab in different countries.
4.4 | Implications for practice and research
While dupilumab shows an improvement for all the important out-
comes for patients with uncontrolled severe asthma, there is a disso-
ciated effect with significant improvement in exacerbation rate and 
OCS use and modest improvement in asthma control, quality of life 
and rescue medication use. The subgroup analysis showed a better 
efficacy for patients with strong T2 inflammation signature (blood 
eosinophils > 300/μL and/or FeNO > 50 ppb). There are limited data 
on the economic impact. In this context, panels are likely to formulate 
conditional rather than strong recommendations for dupilumab use.
Although short-term safety data are reassuring, more accurate 
AE reporting is warranted, in combination with long-term safety 
evaluation, including observational studies and registries. There are 
limited data available to support the efficacy and safety in the pae-
diatric population, highlighting the urgent unmet need for rigorous 
trials with biologicals in children with uncontrolled severe asthma.
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